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Abstract
Acute mountain sickness is the commonest acute high altitude illness occurring at high altitude. Its prevalence is
dependent on the ascent rate, altitude achieved, physical effort required to reach the target altitude and
pharmacological intervention undertaken by the tourists visiting high altitude areas. This Letter to the Editor is an
endeavour to re-emphasise the importance of all these factors affecting the prevalence of acute mountain sickness.
To the Editor
We read with profound interest the article titled ‘Acute
mountain sickness among tourists visiting the high-
altitude city of Lhasa at 3658 m above sea level: a cross-
sectional study’ by Gonggalanzi et al. [1]. Indeed this
study is one of its kind, which involved evaluation of a
large sample size of ordinary travellers to Lhasa for acute
mountain sickness (AMS). As reported by the authors,
47.3% (1022 out of 2160) tourists travelled to Lhasa by
means other than air (by road, rail and train) and 35.9%
of them suffered from AMS. It would be interesting to
know the ascent profile and travel history of these sub-
jects. Their travel details like starting altitudes, travel
time and average ascent rates would have elucidated fur-
ther the effects of mode of travel/induction to high alti-
tude (HA) on occurrence of AMS as many of the travel
related symptoms in HA terrain like fatigue, motion
sickness etc. may imitate symptoms included in ques-
tionnaire based on Lake Louise scoring system (LLSS).
Authors have mentioned that 46.4% (965 out of 2081)
of the tourists used various prophylactic agents in the
present study. As per Wilderness Medical Society guide-
lines, the prophylactic agents generally used against pre-
vention of acute high altitude illnesses are classified into
two groups: one group consisting of drugs used against
AMS/high altitude cerebral edema (acetazolamide, ste-
roids) and other group having drugs used against high
altitude pulmonary edema (nifedipine) [2]. Evaluation of
effects of these drugs as one combined group by the
authors and reporting of occurrence of AMS does not
bring out their actual relationship. It would have been
nice if authors had evaluated the relationship between
AMS and drugs used specifically against it. Also, elabor-
ation on history of drug intake like timings of starting/
stopping medication and dosage would have explained
this relationship better in travellers to Lhasa.
As acknowledged by the authors, AMS is generally
known to occur 6 to 12 h after ascending beyond
2500 m [3]. But the data presented in this study may not
actually support this because of a possible ‘recall’ bias
because of lack of uniformity in filling and submitting
questionnaires based on LLSS. It would have been inter-
esting if the tourists were asked to fill the questionnaires
after a specific time say after 12 or 24 h of ascent to
3658 m. This could have reduced this possible bias and
helped in comparison of outcome of the present study
with other studies at similar altitudes.
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